Carmeda Coating Approved By FDA For Use On Cordis Bx Velocity Stent; Carmeda Technology Now Available On Several Critical Devices.Business Editors & Health/Medical Writers BIOWIRE2K SAN ANTONIO--(BW HealthWire)--Nov. 16, 2000 Use of the Carmeda BioActive Surface (CBAS CBAS Command Budget Automated System CBAS Computrols Building Automation System (building automation software) CBAS Computerized Building Automation System CBAS Corporate Business Applications Support ) has been approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in a Pre-Market Approval (PMA PMA (papillary-marginal-attached), n a system of epidemiologic scoring of periodontal disease devised by Schour and Massler in which the symbols denote the areas involved in gingival inflammation. PMA Progressive muscular atrophy ) dated July 21, 2000 for application to the highly successful Bx Velocity(tm) stent from Cordis. This coronary stent currently is marketed in Europe under the Cordis trade name Bx Velocity with Hepacoat(tm). Previously, Cordis, a Johnson and Johnson company, announced CE-marking of the Bx Velocity coronary stent with the Carmeda coating using the Cordis trademark Hepacoat (http://www.johnsonandjohnson.com/news_finance/212.htm). Cordis joins several other prominent medical device companies which utilize the Carmeda BioActive Surface technology, companies including Medtronic, W.L. Gore & Associates, Diametrics and Pharmacia Corporation. CBAS is a proprietary heparin coating which retains thromboresistant properties for periods lasting several months. This long-term bioactivity bi·o·ac·tiv·i·ty n. The effect of a given agent, such as a vaccine, upon a living organism or on living tissue. , coupled with the fact that the stable heparin coating does not leave the device surface, differentiates CBAS from other coatings designed to improve the hemocompatibility of blood-contacting devices. "The European market launch of the Cordis Bx Velocity stent with Hepacoat, and FDA approval of the Bx Velocity stent with Hepacoat reinforce Carmeda's position as the leader in the hemocompatibility coating market, particularly in critical medical device applications," states Andrew Jacobson, Director of Business Development at Carmeda. The Carmeda coating technology is applied to medical devices for use in babies, adolescents, adults and the elderly. Diametrics coats blood gas sensors used to monitor premature newborns. Adolescents benefit from Carmeda's blood sampling catheter which is used in growth hormone studies. Adults are permanently implanted with Carmeda-coated coronary stents from Cordis and undergo heart bypass surgery with the help of Carmeda-coated Maxima(tm) (www.medtronic.com/cardiac/perfusion/products/bs_carmeda.html) blood oxygenator oxygenator an apparatus by which oxygen is introduced into the blood during circulation outside the body, as during open-heart surgery. See also extracorporeal circulatory support unit. circuits from Medtronic. And the elderly receive intraocular lens implants coated with Carmeda-based technology by Pharmacia Corporation. CBAS is the most prevalent and clinically proven thromboresistant coating applied to critical medical devices by U.S. and European device manufacturers. Since 1985 Carmeda has commercialized the "end-point attachment" of immobilized heparin molecules to medical device surfaces. Carmeda AB (Stockholm) is majority owned by Norsk Hydro ASA Asa (ā`sə), in the Bible, king of Judah, son and successor of Abijah. He was a good king, zealous in his extirpation of idols. When Baasha of Israel took Ramah (a few miles N of Jerusalem), Asa bought the help of Benhadad of Damascus and (ADR ADR - Astra Digital Radio )(NYSE NYSE See: New York Stock Exchange :HYDRO). For additional information please visit www.carmeda.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion